Where the global cancer community meets - daily news, trial breakdowns. KOL interviews, live from major cancer congresses
OncoDaily - The Voice of Oncology
Why 1000 Doctors Gave This Cancer Drug A Standing Ovation? - Dr. Sandler shares how Revolution Medicines evolved from its early beginnings to becoming a leader in RAS-targeted therapies. He explains the scientific rationale behind targeting RAS-driven tumor.
Stanford Cancer Institute Welcomes Pamela Munster as Associate Director for Early Detection and Interception Research
@StanfordCancer
https://t.co/0eEhXNuCez
Bermuda Cancer and Health Centre Expands Access to Cancer Prevention and Support – Union for International Cancer Control (UICC)
@uicc
https://t.co/MX5zqh1KnF
We are pleased to announce Professor @EdwinPosadasMD as a Speaker at VIRO 2026 – Global Voices in Renal Oncology.
Professor Posadas is Professor of Medicine at @CedarsSinai, Co-Leader of the Cancer Therapeutics Program, and Medical Director of the Center for Uro-Oncology Research Excellence. His work focuses on genitourinary cancers, cancer metastasis, liquid biopsies, biomarker development, and precision oncology.
His expertise in genitourinary oncology, translational research, and precision medicine will bring valuable perspective to this international discussion on contemporary kidney cancer management.
Register here: https://t.co/AQEh7GuBW9
Additional faculty announcements will follow soon.
Kalshi is Betting on Trial Results and FDA Decisions Now - What’s Next?
🎲While people were placing bets on the World Cup Final, @Kalshi announced that users can now also bet on clinical drug trials.
In July 2026, Kalshi, an online gambling website, launched a program that lets users put money on clinical trial results and @FDA decisions.
Supposedly, these new markets could bring much-needed honesty to drug development and reveal what company announcements often hide: how much confidence people really have in a drug?
That is the promise. But the moment clinical trial results become subject to a gamble, harder questions appear:
❓Is betting really what the field is missing?
❓Could the odds influence the outcomes?
❓Should people be allowed to make money by predicting whether a medicine succeeds or fails?
Whatever is considered success or failure.
While these questions remain a priority, to better capture the essence of this program, we would love to hear Kalshi’s perspective and vision.
We also invite you to share your take on this with us. Feel free to send an editorial as a feature on this special topic on OncoDaily.
Read the full article: https://t.co/vNajQ30qG1
#Kalshi #Clinicaltrials
This Wednesday on Empowering Oncologists
Host Dr. Jasmine Kamboj (@JasmineKambojMD) is joined by Dr. Anjali Sibley, Director of Stanford Emeryville Cancer Center.
Together, they discuss how supportive care should begin at the moment of diagnosis, why strategic cancer navigation is essential for every patient, and how exercise oncology, community partnerships, and holistic care can improve both patient outcomes and quality of life.
Dr. Sibley also shares insights from her upcoming book on helping patients navigate the cancer journey with confidence and compassion.
Stay tuned and don't miss this inspiring conversation.
Subscribe to OncoDaily TV’s Youtube channel https://t.co/iS3YY7iQ1z -so you don’t miss future conversations like this. It really helps us continue producing conversations like this.